SCHEMBL7983769

SCHEMBL7983769

CNC(=O)c1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.61
JAK1 P23458 1/20 0.61
TYK2 P29597 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
TSHR P16473 1/20 0.52
TRPV1 Q8NER1 1/20 0.49
CRHR1 P34998 5/20 0.48
ALDH1A1 P00352 3/20 0.48
CYP1A2 P05177 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
ANO1 Q5XXA6 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KCNH2 Q12809 1/20 0.47
CES2 O00748 1/20 0.46
KDM4E B2RXH2 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13145527 0.85 SMN1; SMN2 (0.51) JAK2JAK1TYK2SMN1; SMN2ALDH1A1
SCHEMBL13485796 0.85 JAK2 (0.62) JAK2JAK1TYK2SMN1; SMN2LMNA
SCHEMBL4352363 0.83 JAK2 (0.61) JAK2JAK1TYK2SMN1; SMN2LMNA
SCHEMBL24073216 0.83 ALDH1A1 (0.62) JAK2JAK1TYK2SMN1; SMN2LMNA
SCHEMBL13753890 0.83 JAK2 (0.57) JAK2JAK1TYK2SMN1; SMN2LMNA
SCHEMBL13753374 0.83 JAK2 (0.57) JAK2JAK1TYK2SMN1; SMN2LMNA
SCHEMBL8572515 0.81 SORT1 (0.49) SMN1; SMN2LMNAALDH1A1CES2KDM4E
SCHEMBL11832781 0.81 CES2 (0.66) SMN1; SMN2LMNAALDH1A1CES2KDM4E
SCHEMBL14214021 0.81 KDM4E (0.53) SMN1; SMN2LMNAHPGDTSHRTRPV1
SCHEMBL1199588 0.81 JAK2 (0.57) JAK2JAK1TYK2SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 JAK2 2148/4885JAK1 1029/4885TYK2 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.